Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben-Horin

Showing results (191-200 of 362) with videos related to

Pageof 37
Sort By:
Alimentary Pharmacology & Therapeutics|June 3, 2015
Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawalS Ben-Horin, Y Chowers, B Ungar, et al.
Journal of Crohn'S & Colitis|July 29, 2014
Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysisUri Kopylov, Talal Al-Taweel, Mohammad Yaghoobi, et al.
Gut|June 4, 2010
The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically usefulShomron Ben-Horin, Miri Yavzori, Lior Katz, et al.
Journal of Crohn'S & Colitis|December 1, 2021
Differential Serum-intestinal Dynamics of Infliximab and Adalimumab in Inflammatory Bowel Disease PatientsHaggai Bar-Yoseph, Alexandra Blatt, Shiran Gerassy, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 9, 2025
Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to AdalimumabMaya Granot, Nurit Nachum, Alexander Krauthammer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 26, 2010
TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive functionMeital Nagar, Jasmine Jacob-Hirsch, Helly Vernitsky, et al.
The Israel Medical Association Journal : IMAJ|May 5, 2017
Combination of Corticosteroids with 5-Aminosalicylic Acids Compared to Corticosteroids Alone for Hospitalized Patients with Active Ulcerative ColitisOfir Har-Noy, Bun Kim, Rivi Haiat, et al.
Clinical Drug Investigation|April 2, 2023
Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical TrialGeert D'Haens, Walter Reinisch, Stefan Schreiber, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 6, 2015
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel DiseasesBella Ungar, Idan Levy, Yarden Yavne, et al.
United European Gastroenterology Journal|April 26, 2019
Rising prevalence of celiac disease is not universal and repeated testing is needed for population screeningRachel Levinson-Castiel, Rami Eliakim, Eilat Shinar, et al.
Pageof 37

Showing results (191-200 of 362) with videos related to

Sort By:
Pageof 37
Alimentary Pharmacology & Therapeutics|June 3, 2015
Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawalS Ben-Horin, Y Chowers, B Ungar, et al.
Journal of Crohn'S & Colitis|July 29, 2014
Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysisUri Kopylov, Talal Al-Taweel, Mohammad Yaghoobi, et al.
Gut|June 4, 2010
The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically usefulShomron Ben-Horin, Miri Yavzori, Lior Katz, et al.
Journal of Crohn'S & Colitis|December 1, 2021
Differential Serum-intestinal Dynamics of Infliximab and Adalimumab in Inflammatory Bowel Disease PatientsHaggai Bar-Yoseph, Alexandra Blatt, Shiran Gerassy, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 9, 2025
Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to AdalimumabMaya Granot, Nurit Nachum, Alexander Krauthammer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 26, 2010
TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive functionMeital Nagar, Jasmine Jacob-Hirsch, Helly Vernitsky, et al.
The Israel Medical Association Journal : IMAJ|May 5, 2017
Combination of Corticosteroids with 5-Aminosalicylic Acids Compared to Corticosteroids Alone for Hospitalized Patients with Active Ulcerative ColitisOfir Har-Noy, Bun Kim, Rivi Haiat, et al.
Clinical Drug Investigation|April 2, 2023
Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical TrialGeert D'Haens, Walter Reinisch, Stefan Schreiber, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 6, 2015
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel DiseasesBella Ungar, Idan Levy, Yarden Yavne, et al.
United European Gastroenterology Journal|April 26, 2019
Rising prevalence of celiac disease is not universal and repeated testing is needed for population screeningRachel Levinson-Castiel, Rami Eliakim, Eilat Shinar, et al.
Pageof 37